Vivoryon Therapeutics N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
23 mrt 2016 - 08:07
Statutaire naam
Vivoryon Therapeutics N.V.
Titel
Probiodrug Appoints Mark Booth as Chief Business Officer
Bericht
Expands Management Board with Senior Hire
HALLE/SAALE, Germany, 23 March 2016 - Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease, today announced that Mark Booth has joined the company as Chief Business Officer and member of the Management Board. Mr. Booth brings over 30 years of biopharmaceutical experience to Probiodrug.
"Mark's broad business background and proven track record make him a valuable addition to our management board," said Dr. Erich Platzer, Chairman of the Supervisory Board of Probiodrug. "His extensive experience in business development and investor relations will be instrumental to propel Probiodrug's strategy internationally and in particular the United States."
Datum laatste update: 18 februari 2025